Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.50 |
| ▸ | LCK | P06239 | 6/20 | 0.50 |
| ▸ | SRC | P12931 | 4/20 | 0.50 |
| ▸ | KIT | P10721 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | YES1 | P07947 | 2/20 | 0.50 |
| ▸ | LYN | P07948 | 2/20 | 0.50 |
| ▸ | HCK | P08631 | 2/20 | 0.50 |
| ▸ | BCR | P11274 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | FGR | P09769 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | SIK2 | Q9H0K1 | 11/20 | 0.48 |
| ▸ | SIK3 | Q9Y2K2 | 11/20 | 0.48 |
| ▸ | SIK1 | P57059 | 9/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254834 | 0.90 | LCK (0.52) | ABL1LCKSRCKITEGFR | |
| SCHEMBL21495194 | 0.89 | SIK2 (0.48) | ABL1LCKSRCKITEGFR | |
| SCHEMBL12445981 | 0.87 | LCK (0.52) | ABL1LCKSRCKITEGFR | |
| SCHEMBL20633817 | 0.87 | RAB9A (0.52) | ABL1LCKSRCKITEGFR | |
| SCHEMBL22964566 | 0.85 | LCK (0.56) | ABL1LCKSRCKITEGFR | |
| SCHEMBL14141840 | 0.85 | LCK (0.50) | ABL1LCKSRCKITEGFR | |
| SCHEMBL14141815 | 0.85 | LCK (0.50) | ABL1LCKSRCKITEGFR | |
| SCHEMBL27773162 | 0.84 | FLT3 (0.48) | ABL1LCKSRCKITEGFR | |
| SCHEMBL22964561 | 0.79 | LCK (0.60) | ABL1LCKSRCKITEGFR | |
| SCHEMBL21875018 | 0.79 | LCK (0.67) | ABL1LCKSRCKITEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109265455-B | Preparation method of dasatinib | 新发药业有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | CERBIOS-PHARMA SA (CH) | 2015-09-17 | — | — | US | disclosed |
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | CERBIOS-PHARMA SA (CH) | 2015-09-17 | — | — | US | disclosed |
| EP-2918584-A1 | Process and intermediates for the preparation of dasatinib | Cerbios-Pharma S.A. (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2918584-A1 | Process and intermediates for the preparation of dasatinib | Cerbios-Pharma S.A. (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9115124-B1 | Process and intermediates for the preparation of dasatinib | CERBIOS-PHARMA SA (CH) | 2015-08-25 | — | — | US | disclosed |
| US-9115124-B1 | Process and intermediates for the preparation of dasatinib | CERBIOS-PHARMA SA (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | ABL1 1/4885LCK 56/4885SRC 11/4885 |
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | ABL1, SRC, ABL2 | ABL1 1/4885LCK 17/4885SRC 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.